PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH

Current Bladder Dysfunction Reports

Volumn 8, Issue 2, 2013, Pages 150-159

  Gacci, M ^a   Sebastianelli, A ^a   Salvi, M ^a   Vignozzi, L ^a   Corona, G ^b   McVary, K T ^c   Kaplan, S A ^d   Oelke, M ^e   Maggi, M ^a   Carini, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c NORTHWESTERN UNIVERSITY   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Benign prostatic hyperplasia; BPH; ED; Erectile dysfunction; IIEF; IPSS; Lower urinary tract symptoms; LUTS; PDE5; PDE5 I; Prostate

Indexed keywords

ALFUZOSIN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; TAMSULOSIN; VARDENAFIL;

BACKACHE; CANCER SCREENING; COMORBIDITY; COUGHING; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEADACHE; HEALTH SURVEY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTERNATIONAL INDEX OF ERECTILE FUNCTION; LOWER URINARY TRACT SYMPTOM; PATHOPHYSIOLOGY; PREVALENCE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCORING SYSTEM; SINUSITIS; TREATMENT RESPONSE;

EID: 84878337710     PISSN: 19317212     EISSN: 19317220     Source Type: Journal    
DOI: 10.1007/s11884-013-0184-9     Document Type: Review

References (81)

1. •• Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60: 809-25. A comprehensive analysis of the relationship among sexual dysfunction lower urinary tract symptoms due to benign prostatic hyperplasia, and related therapies, with a critical analysis of PDE5-Is usefulness in LUTS/BPH, including preclinical and clinical research data.
2. Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30: 292-301.
3. •• Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61: 994-1003. A systematic review and meta-analysis of available prospective and cross-sectional studies on the use of PDE5-Is for BPH related LUTS.
4. Zhao C, Kim SH, Lee SW, et al. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 2011;107: 1943-7.
5. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology. 2007;148: 1019-29.
6. Kaplan SA, Hatzichristou D. Open to debate. The motion: PDE5 inhibitors will have a significant role in the treatment of BPH. Eur Urol. 2007;52: 1523-7.
7. • Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, et al. Characterization of phosphodiesterasetype 5 expression and functional activity in the human male lower urinary tract. J Sex Med. 2010;7: 59-69. An interesting work on the characterization and activity of phosphodiesterase type 5 expression in the human male lower urinary tract.
8. Morelli A, Chavalmane AK, Filippi S, Fibbi B, Silvestrini E, Sarchielli E, et al. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signalling hyper-activation. J Sex Med. 2009;6: 91-106.
9. Morelli A, Filippi S, Sandner P, Fibbi B, Chavalmane AK, Silvestrini E, et al. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med. 2009;6: 1594-608.
10. Gacci M, Del Popolo G, Macchiarella A, Celso M, Vittori G, Lapini A, et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol. 2007;178: 2040-3. discussion 2044.
11. Gacci M, Ierardi A, Rose AD, Tazzioli S, Scapaticci E, Filippi S, et al. Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study. J Sex Med. 2010;7: 234-43.
12. Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 2011;8: 2746-60.
13. Morelli A, Filippi S, Comeglio P, Sarchielli E, Chavalmane AK, Vignozzi L, et al. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med. 2010;7: 107-20.
14. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States. Prevalence and predictors. JAMA. 1999;281: 537-44.
15. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the "Cologne Male Survey". IJIR. 2000;12: 305-11.
16. Shiri R, Häkkinen J, Koskimäki J, Hakama M, Tammela TL, Auvinen A. Erectile dysfunction influences the subsequent incidence of lower urinary tract symptoms and bother. Int J Impot Res. 2007;19: 317-20.
17. Morant S, Bloomfield G, Vats V, Chapple C. Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms. J Sex Med. 2009;6: 1103-10.
18. McVary K, Foley KA, Long SR, Sander S, Curtice TG, Shah H. Identifying patients with benign prostatic hyperplasia through a diagnosis of, or treatment for, erectile dysfunction. Curr Med Res Opin. 2008;24: 775-84.
19. Antunes AA, Srougi M, Dall'oglio MF, Vicentini F, Paranhos M, Freire GC. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening. J Sex Med. 2008;5: 1702-7.
20. Nicolosi A, Glasser DB, Moreira ED, Villa M. Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study. Int J Impot Res. 2003;15: 253-7.
21. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R, et al. The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. BJU Int. 2003;92: 719-25.
22. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44: 637-49.
23. Holden CA, McLachlan RI, Pitts M, Cumming R, Wittert G, Ehsani JP, et al. Determinants of male reproductive health disorders: the Men in Australia Telephone Survey (MATeS). BMC Publ Health. 2010;10: 961-9.
24. Wein AJ, Coyne KS, Tubaro A, Sexton CC, Kopp ZS, Aiyer LP. The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int. 2009;103 Suppl 3: 33-41.
25. Frankel SJ, Donovan JL, Peters TI, Abrams P, Dabhoiwala NF, Osawa D, et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol. 1998;51: 677-85.
26. Li MK, Garcia L, Patron N, Moh LC, Sundram M, Leungwattanakij S, et al. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function. BJU Int. 2008;101: 197-202.
27. Corona G, Lee DM, Forti G, O'Connor DB, Maggi M, O'Neill TW, et al. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med. 2010;7: 1362-80.
28. Moon A. Influence of nitric oxide signalling pathways on pre-contracted human detrusor smooth muscle in vitro. BJU Int. 2002;89: 942-9.
29. Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: Clinical implications in men with lower urinary tract symptoms. World J Urol. 2008;26: 603-9.
30. Dixon JS, Jen PY. Development of nerves containing nitric oxide synthase in the human male urogenital organs. Br J Urol. 1995;76: 719-25.
31. Hedlund P. Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract-is there a basis for pharmacological targeting of cGMP? World J Urol. 2005;23: 362-7.
32. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182: 4056-64.
33. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010;7: 524-40.
34. Morelli A, Vignozzi L, Filippi S, Vannelli GB, Ambrosini S, Mancina R, et al. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate. 2007;67: 234-47.
35. Fibbi B, Morelli A, Marini M, Zhang XH, Mancina R, Vignozzi L, et al. Atorvastatin but not elocalcitol increases sildenafil responsiveness in spontaneously hypertensive rats by regulating the RhoA/ROCK pathway. J Androl. 2008;29: 70-84.
36. Wibberley A, Chen Z, Hu E, Hieble JP, Westfall TD. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br J Pharmacol. 2003;138: 757-66.
37. Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B, et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med. 2009;6: 3274-88.
38. Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L, et al. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol. 2012;132: 80-92.
39. Rajasekaran M, Wilkes N, Kuntz S, E Albo M. Rho-kinase inhibition suppresses bladder hyperactivity in spontaneously hypertensive rats. Neurourol Urodyn. 2005;24: 295-300.
40. Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia. 2006;38: 1-12.
41. Rahman NU, Phonsombat S, Bochinski D, Carrion RE, Nunes L, Lue TF. An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat. BJU Int. 2007;100: 658-63.
42. McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2005;174: 1327-33.
43. Golomb E, Rosenzweig N, Eilam R, et al. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl. 2000;21: 58-64.
44. Persson K, Pandita RK, Spitsbergen JM, et al. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol. 1998;275: R1366-73.
45. Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol. 2006;50: 721-31.
46. Berger AP, Deibl M, Leonhartsberger N, et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005;96: 1073-8.
47. Ghafar MA, Anastasiadis AG, Olsson LE, Chichester P, Kaplan SA, Buttyan R, et al. Hypoxia and an angiogenic response in the partially obstructed rat bladder. Lab Invest. 2002;82: 903-9.
48. Tarcan T, Azadzoi KM, Siroky MB, Goldstein I, Krane RJ. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol. 1998;82 Suppl 1: 26-33.
49. Du Z, Fujiyama C, Chen Y, et al. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin Med J (Engl). 2003;116: 1936-9.
50. Lekas AG, Lazaris AC, Chrisofos M, et al. Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia. Urology. 2006;68: 436-41.
51. Vignozzi L, Filippi S, Morelli A, Marini M, Chavalmane A, Fibbi B, et al. Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism. J Sex Med. 2009;6: 1270-83.
52. Vignozzi L, Morelli A, Filippi S, Vannelli GB, Mungai S, Marini M, et al. Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat. Int J Impot Res. 2008;20: 60-7.
53. Vignozzi L, Filippi S, Morelli A, Ambrosini S, Luconi M, Vannelli GB, et al. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med. 2006;3: 419-31.
54. Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, Cellai I, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol. 2012;212: 71-84.
55. Caremel R, Oger-Roussel S, Behr-Roussel D, Grise P, Giuliano FA. Nitric oxide/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat. Eur Urol. 2010;58: 616-25.
56. Gonzalez RR, Kaplan SA. Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Expert Opin Drug Metab Toxicol. 2006;2: 609-17.
57. • Uckert S, Oelke M. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol. 2011;72: 197-204. A focus on the potential use and clinical significance of PDE inhibitors in the treatment of LUTS, and the activity of PDE isoenzymes.
58. McVary K, Tubaro A, De Nunzio C. Open to debate. The motion: PDE5 inhibitors are a promising therapy for benign prostatic hyperplasia. Eur Urol. 2009;56: 878-80.
59. Mouli S, McVary KT. PDE5 inhibitors for LUTS. Prostate Cancer Prostatic Dis. 2009;12: 316-24.
60. Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P, et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol. 2012;214: 31-43.
61. Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009;69: 480-93.
62. Gacci M, Bartoletti R, Figlioli S, Sarti E, Eisner B, Boddi V, et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int. 2003;91: 196-200.
63. Uckert S, Sigl K, Waldkirch ES, Sandner P, Ulbrich E, Oelke M, et al. Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function. An immunohistochemical and functional study. Urologe A. 2009;48: 764-9.
64. Uckert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol. 2006;49: 740-5.
65. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90: 836-9.
66. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med. 2006;3: 662-7.
67. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177: 1401-7.
68. Liu L, Zheng S, Han P, Wei Q. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Urology. 2011;77: 123-9.
69. Laydner HK, Oliveira P, Oliveira CR, et al. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. BJU Int. 2011;107: 1104-9.
70. McVary KT, Monnig W, Camps Jr JL, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177: 1071-7.
71. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51: 1717-23.
72. Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol. 2010;28: 17-22.
73. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180: 1228-34.
74. Porst H, McVary KT, Montorsi F, et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. 2009;727: 36. Corrigendum. Eur Urol. 2011;59: 1082.
75. Porst H, Kim ED, Casabé AR, for the LVHJ study team, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol. 2011;60: 1105-13.
76. Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61: 917-25.
77. Donatucci CF, Brock GB, Goldfischer ER, Pommerville PJ, Elion-Mboussa A, Kissel JD, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int. 2011;107: 1110-6.
78. Bechara A, Romano S, Casabé A, et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH pilot study. J Sex Med. 2008;5: 2170-8.
79. Liguori G, Trombetta C, De Giorgi G, et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. preliminary report. J Sex Med. 2009;6: 544-52.
80. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53: 1236-44.
81. Gacci M, Vittori G, Tosi N, et al. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0. 4 mg vs. tamsulosin 0. 4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9: 1624-33.